Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 4/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.41 |
| ▸ | CDC25B | P30305 | 7/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26658233 | 0.86 | TACR2 (0.44) | TACR2NT5EBCHEPTPN1CDC25B | |
| SCHEMBL22288928 | 0.83 | TACR2 (0.56) | TACR2NT5EBCHEPTPN1CDC25B | |
| SCHEMBL22288930 | 0.81 | TACR2 (0.54) | TACR2NT5EBCHEPTPN1CDC25B | |
| SCHEMBL22288934 | 0.80 | TACR2 (0.53) | TACR2NT5EBCHEPTPN1CDC25B | |
| SCHEMBL22288933 | 0.77 | TACR2 (0.49) | TACR2NT5EBCHEPTPN1CDC25B | |
| SCHEMBL22704686 | 0.76 | TACR2 (0.51) | TACR2NT5EPTPN1CDC25BPTPN2 | |
| SCHEMBL20804346 | 0.75 | TACR2 (0.47) | TACR2NT5E | |
| SCHEMBL18405449 | 0.74 | TACR2 (0.58) | TACR2NT5EBCHEPTPN1CDC25B | |
| SCHEMBL278501 | 0.74 | TACR2 (0.54) | TACR2NT5EBCHEPTPN1CDC25B | |
| SCHEMBL10743096 | 0.73 | TACR2 (0.45) | TACR2NT5EBCHEPTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | JANSSEN BIOPHARMA, LLC | 2023-11-16 | — | — | US | disclosed |
| EP-3917922-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen BioPharma, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020157694-A9 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen Biopharma, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2020157694-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen Biopharma, Inc. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365608-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | PNP, NUDT1, ADAR | TACR2 4856/4885NT5E 34/4885BCHE 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.